Hexarelin (2mg x 10), CJC-1295 no DAC (2mg x 10)

Hexarelin and CJC-1295 no DAC (Mod GRF 1-29) are synthetic research peptides used together in experimental models to investigate growth hormone axis regulation and somatotropic signaling pathways. Hexarelin is a potent hexapeptide growth hormone secretagogue that binds the growth hormone secretagogue receptor (GHS-R1a), activating Gq/PLC-dependent calcium signaling involved in GH release and hypothalamic–pituitary feedback mechanisms. CJC-1295 no DAC is a stabilized analog of growth hormone–releasing hormone (GHRH 1-29) that selectively activates the GHRH receptor, stimulating adenylate cyclase and cAMP-mediated signaling in pituitary somatotrophs. Preclinical research utilizes the combined activation of GHS-R1a and GHRH receptors to examine synergistic GH secretion, receptor pharmacology, and endocrine signaling dynamics in controlled laboratory settings.